Global Blood Therapeutics, Inc. (NASDAQ:GBT) has been assigned a consensus rating of “Buy” from the fifteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $52.91.

A number of equities analysts have recently weighed in on the stock. BidaskClub raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Cowen and Company reaffirmed an “outperform” rating and issued a $83.00 price target on shares of Global Blood Therapeutics in a research note on Monday, August 14th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $46.00 price target (up from $44.00) on shares of Global Blood Therapeutics in a research note on Tuesday, August 8th. ValuEngine raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Global Blood Therapeutics in a research note on Tuesday, July 11th.

In other news, Director Deval L. Patrick sold 27,053 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total value of $803,203.57. Following the sale, the director now directly owns 12,053 shares of the company’s stock, valued at $357,853.57. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 143,255 shares in the company, valued at $4,297,650. The disclosure for this sale can be found here. Insiders have sold 33,053 shares of company stock worth $983,204 over the last three months. Company insiders own 5.30% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GBT. BlackRock Inc. lifted its stake in shares of Global Blood Therapeutics by 4,675.5% in the first quarter. BlackRock Inc. now owns 2,618,847 shares of the company’s stock valued at $96,503,000 after buying an additional 2,564,008 shares during the period. State Street Corp lifted its stake in shares of Global Blood Therapeutics by 217.9% in the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock valued at $58,479,000 after buying an additional 1,465,595 shares during the period. White Square Capital LLP bought a new stake in shares of Global Blood Therapeutics in the first quarter valued at about $53,593,000. Janus Henderson Group PLC bought a new stake in shares of Global Blood Therapeutics in the second quarter valued at about $26,919,000. Finally, Perceptive Advisors LLC lifted its stake in shares of Global Blood Therapeutics by 23.3% in the first quarter. Perceptive Advisors LLC now owns 3,858,978 shares of the company’s stock valued at $142,203,000 after buying an additional 730,000 shares during the period. Institutional investors and hedge funds own 86.07% of the company’s stock.

Global Blood Therapeutics (GBT) traded down 0.19% during midday trading on Friday, reaching $26.40. The company’s stock had a trading volume of 453,366 shares. The stock’s 50-day moving average price is $27.84 and its 200-day moving average price is $30.08. The firm’s market capitalization is $1.15 billion. Global Blood Therapeutics has a 12 month low of $13.35 and a 12 month high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.06. During the same quarter last year, the company earned ($0.58) earnings per share. Analysts predict that Global Blood Therapeutics will post ($2.45) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set Global Blood Therapeutics, Inc. (GBT) PT at $52.91” was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/14/brokerages-set-global-blood-therapeutics-inc-gbt-pt-at-52-91.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.